The U.S. Food and Drug Administration (FDA) has approved Altuviiio, a groundbreaking Hemophilia A therapy developed by Sanofi. This therapy uses advanced recombinant technology to extend the drug’s time in circulation and improve clotting factor stability, offering a significant edge over older therapies.
Unlike traditional treatments, Altuviiio offers once-weekly dosing, significantly reducing the burden of frequent infusions for patients.
This innovative therapy extends protection from bleeds with a 3 to 4 times longer half-life compared to existing factor VIII treatments. It is also the first therapy to bypass the von Willebrand factor limitation, allowing for prolonged effectiveness.
Clinical trials have shown that Altuviiio reduces annual bleeding rates, improves bleeding control and enhances patient quality of life by minimizing spontaneous bleeds and the frequency of infusions. Experts believe this approval marks a major advancement in hemophilia care, providing a more convenient and effective treatment option.
Additionally, its extended circulation time may reduce the need for emergency interventions, offering greater stability for individuals managing hemophilia A.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare professional for diagnosis and treatment options.
